{
    "nct_id": "NCT03792841",
    "official_title": "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer",
    "inclusion_criteria": "* Subject has provided informed consent prior to initiation of any study specific activities/procedures\n* Subjects with histologically or cytologically confirmed mCRPC who are refractory to a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the non-metastatic CRPC setting\n* Subjects must have undergone bilateral orchiectomy or must be on continuous ADT with a gonadotropin releasing hormone (GnRH) agonist or antagonist\n* Total serum testosterone </= 50 ng/dL or 1.7 nmol/L\n* Evidence of progressive disease, defined as 1 or more PCWG3 criteria:\n* PSA level >/= 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart\n* nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications\n* appearance of 2 or more new lesions in bone scan\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1\n* Life expectancy >/= 6months\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for >/= 30 days prior to randomization are eligible\n* Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed with Amgen medical monitor prior to enrollment)\n* Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression\n* Active autoimmune disease or any other diseases requiring immunosuppressive therapy while on study\n* Needing chronic systemic corticosteroid therapy (prednisone > 10 mg per day or equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose\n* Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication, and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months of first dose of acapatamab\n\nPart 2 only:\n\n* Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a Grade 3 or higher immune-related adverse event prior to first day of dosing\n* History or evidence of interstitial lung disease or active, non-infectious pneumonitis\n\nPart 3 only:\n\n- Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of investigational product\n\nPart 6 only:\n\nSubjects are excluded from this cohort if any of the following additional criteria apply:\n\n* Subjects taking strong OAT3 inhibitors (eg, probenecid) or adjust the dosing to 1 mg PO QD.\n* Subjects with latent or active tuberculosis at screening",
    "miscellaneous_criteria": "All Parts"
}